Clinical Trial Results:
Envarsus® tablets administered once daily in combination with everolimus in elderly de-novo kidney transplant recipients: open-label, multicentre, single-arm, pharmacokinetic and clinical study
Summary
|
|
EudraCT number |
2015-005640-34 |
Trial protocol |
IT |
Global end of trial date |
22 Feb 2018
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
28 Feb 2019
|
First version publication date |
28 Feb 2019
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
DFIDM-1501
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02970630 | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
NA: NA | ||
Sponsors
|
|||
Sponsor organisation name |
Chiesi Farmaceutici S.p.A.
|
||
Sponsor organisation address |
Via Palermo 26/A, Parma, Italy, 43122
|
||
Public contact |
Clinical Trial Trasparency, Clinical Trial Trasparency, clinicaltrials_info@chiesi.com
|
||
Scientific contact |
Clinical Trial Trasparency, Clinical Trial Trasparency, clinicaltrials_info@chiesi.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
22 Feb 2018
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
22 Feb 2018
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To estimate tacrolimus (Envarsus®) pharmacokinetic parameters (AUC24, Cmin, Cmin/daily dose and AUC24/daily dose) in elderly de-novo kidney transplant recipients of ECD kidney grafts treated with Envarsus® prolonged release tablets in combination with everolimus tablets (Certican®).
|
||
Protection of trial subjects |
The protocol, together with all required clinical trial documentation, was submitted to the appropriate independent ethics committee (IEC) in all participating sites. A copy of the favourable opinion from the IEC had to be received before the trial could be initiated at an investigational site. The membership of each IEC was also obtained.
The study was performed in compliance with the ‘Declaration of Helsinki’, International Conference of Harmonization Tripartite Guidelines Guideline for Good Clinical Practice (ICH GCP), current international and national regulations, the study protocol and current Standard Operating Procedures (SOPs) of Chiesi Farmaceutici S.p.A.
The consent document met all applicable local laws and provided the patient with information regarding the purpose, procedures, requirements and restrictions of the study, along with any known risks and potential benefits associated with the investigational product and the established provisions for maintaining the confidentiality of personal information. Subject’s written informed consent obtained prior to transplant intervention and prior to any study-related procedures.
|
||
Background therapy |
Envarsus® is a new tacrolimus tablet formulation approved by the European Medicines Agency (EMA). Envarsus®, designed for once-daily administration, was developed utilising the MeltDoseTM drug delivery technology, which increases the bioavailability of poorly water-soluble compounds via solid formulation at molecular state. For this reason, the daily dose should be reduced by 30% in comparison with standard tacrolimus (with the exclusion of black patients), in order to reach the therapeutic exposure to tacrolimus. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
09 Feb 2017
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Italy: 28
|
||
Worldwide total number of subjects |
28
|
||
EEA total number of subjects |
28
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
9
|
||
From 65 to 84 years |
19
|
||
85 years and over |
0
|
|
|||||||||||
Recruitment
|
|||||||||||
Recruitment details |
Twenty-eight (28) patients were enrolled in the study in four (4) Italian sites. There were no screening failures. Of the 28 enrolled patients, 22 (78.6%) completed the study and 6 (21.4%) were discontinued (all due to adverse events). | ||||||||||
Pre-assignment
|
|||||||||||
Screening details |
The screening visit (V1) embraced a period of 24 hours before and after kidney transplantation (Tx). In case of unsuccessful transplantation, transplant failure or if the patient was withdrawn from study before the first dose of study treatments, the subject was to be classified as screening failure and replaced. | ||||||||||
Period 1
|
|||||||||||
Period 1 title |
Treatment period (overall period)
|
||||||||||
Is this the baseline period? |
Yes | ||||||||||
Allocation method |
Non-randomised - controlled
|
||||||||||
Blinding used |
Not blinded | ||||||||||
Arms
|
|||||||||||
Arm title
|
Study Treatment | ||||||||||
Arm description |
all the subjects receiving the study drugs (Envarsus® and everolimus) | ||||||||||
Arm type |
Experimental | ||||||||||
Investigational medicinal product name |
1_Envarsus®
|
||||||||||
Investigational medicinal product code |
|||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Prolonged-release tablet
|
||||||||||
Routes of administration |
Oral use
|
||||||||||
Dosage and administration details |
Reference product: Envarsus® prolonged-release tablets, oral formulation.
Active ingredient: tacrolimus monohydrate.
Dose:
IMP dosage form: 0.75 mg, 1.0 mg and 4.0 mg dosage strengths.
Oral administration once daily
Starting dose: 0.07 mg/kg/day
The dose of Envarsus® was maintained constant until Day 3. Starting from Day 4, the initial tacrolimus dose was adjusted in order to maintain tacrolimus Ctrough within the following target: 4-7 ng/ml until end of Month 3, then 3-6 ng/ml.
|
||||||||||
Investigational medicinal product name |
2_Certican®
|
||||||||||
Investigational medicinal product code |
|||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||
Routes of administration |
Oral use
|
||||||||||
Dosage and administration details |
Reference product: Certican® tablets, oral formulation.
Active ingredient: everolimus
Dose:
IMP dosage form: 0.25 mg and 0.75 mg dosage strengths.
Oral administration twice daily
Starting dose: 2 mg/day
The dose of everolimus was maintained constant until Day 3. Starting from Day 4, the initial dose was adjusted in order to maintain everolimus Ctrough within the following target: 3-8 ng/ml (5-8 ng/ml if determined with immunoassay).
|
||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Treatment period
|
||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Active Treatment Arm with Envarsus tablets administred once daily in combination with Everolimus (Certican®). Envarsus® Active ingredient: tacrolimus monohydrate Oral administration once daily Starting dose: 0.07 mg/kg/day The dose of Envarsus® was maintained constant until Day 3. Starting from Day 4, the initial tacrolimus dose was adjusted in order to maintain tacrolimus Ctrough within the following target: 4-7 ng/ml until end of Month 3, then 3-6 ng/ml. Certican® Active ingredient: everolimus Oral administration twice daily Starting dose: 2 mg/day The dose of everolimus was maintained constant until Day 3. Starting from Day 4, the initial dose was adjusted in order to maintain everolimus Ctrough within the following target: 3-8 ng/ml (5-8 ng/ml if determined with immunoassay). | ||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Study Treatment
|
||
Reporting group description |
all the subjects receiving the study drugs (Envarsus® and everolimus) |
|
|||||||||
End point title |
1_Tacrolimus AUC24 [1] | ||||||||
End point description |
A 24-hour multiple blood sampling for PK assessment was performed on Visit 6 (study Day 10 to 12). Thirteen (13) samples for the determination of tacrolimus concentrations in whole blood in the 0-24 h interval were taken at the following times: 0.00 (within 5 minutes before the morning dose), 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 16.00, 20.00 and 24.00 h post-dose. Area under the whole blood drug concentration curve observed from time 0 to 24 hours post dose was computed using the linear trapezoidal rule. Overall results have been reported.
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
Visit 6 (Day 10 to Day 12)
|
||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Due to the study design (only one arm, without any comparator), primary endpoint's statistical analysis is a descriptive analysis. |
|||||||||
|
|||||||||
Notes [2] - PK population |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
2_Tacrolimus Cmin [3] | ||||||||
End point description |
A 24-hour multiple blood sampling for PK assessment was performed on Visit 6 (study Day 10 to 12). Thirteen (13) samples for the determination of tacrolimus concentrations in whole blood in the 0-24 h interval were taken at the following times: 0.00 (within 5 minutes before the morning dose), 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 16.00, 20.00 and 24.00 h post-dose. Minimum observed blood concentration following a single dose, obtained directly from the blood concentration versus time curves. It was obtained directly from the experimental data without interpolation. Overall results have been reported.
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
Visit 6 (Day 10 to Day 12)
|
||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Due to the study design (only one arm, without any comparator), primary endpoint's statistical analysis is a descriptive analysis. |
|||||||||
|
|||||||||
Notes [4] - PK population |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
3_Tacrolimus Cmax | ||||||||
End point description |
A 24-hour multiple blood sampling for PK assessment was performed on Visit 6 (study Day 10 to 12). Thirteen (13) samples for the determination of tacrolimus concentrations in whole blood in the 0-24 h interval were taken at the following times: 0.00 (within 5 minutes before the morning dose), 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 16.00, 20.00 and 24.00 h post-dose. Maximum observed blood concentration (Cmax) following a single dose, obtained directly from the blood concentration versus time curves. It was obtained directly from the experimental data without interpolation. Overall results have been reported.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Visit 6 (Day 10 to Day 12)
|
||||||||
|
|||||||||
Notes [5] - PK population |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
4_Tacrolimus tmax | ||||||||
End point description |
A 24-hour multiple blood sampling for PK assessment was performed on Visit 6 (study Day 10 to 12). Thirteen (13) samples for the determination of tacrolimus concentrations in whole blood in the 0-24 h interval were taken at the following times: 0.00 (within 5 minutes before the morning dose), 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 16.00, 20.00 and 24.00 h post-dose. Time from dosing to Cmax (tmax), reported using actual times. Overall results have been reported.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Visit 6 (Day 10 to Day 12)
|
||||||||
|
|||||||||
Notes [6] - PK population |
|||||||||
No statistical analyses for this end point |
|
|||||||
End point title |
5_Tacrolimus linear correlation coefficient between AUC24 and Cmin | ||||||
End point description |
A 24-hour multiple blood sampling for PK assessment was performed on Visit 6 (study Day 10 to 12). Thirteen (13) samples for the determination of tacrolimus concentrations in whole blood in the 0-24 h interval were taken at the following times: 0.00 (within 5 minutes before the morning dose), 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 16.00, 20.00 and 24.00 h post-dose. Time from dosing to Cmax, reported using actual times.
Linear correlation refers to linear correlation coefficient (R2) between AUC24 and Cmin.
Overall results have been reported expressed as a pure number to be multiplied by 10(-4).
|
||||||
End point type |
Secondary
|
||||||
End point timeframe |
Visit 6 (Day 10 to Day 12)
|
||||||
|
|||||||
Notes [7] - PK population |
|||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
6_Everolimus day time AUC12 | ||||||||
End point description |
A 24-hour multiple blood sampling for PK assessment was performed on Visit 6 (study Day 10 to 12). Thirteen (13) samples for the determination of tacrolimus concentrations in whole blood in the 0-24 h interval were taken at the following times: 0.00 (within 5 minutes before the morning dose), 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 16.00, 20.00 and 24.00 h post-dose.
Area under the whole blood drug concentration curve observed from time 0 to 12 hours post dose (AUC12, day time) was computed using the linear trapezoidal rule. Overall results have been reported.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Visit 6 (Day 10 to Day 12) - day time
|
||||||||
|
|||||||||
Notes [8] - PK population |
|||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
7_Everolimus day time Cmin and Cmax | ||||||||||||
End point description |
A 24-hour multiple blood sampling for PK assessment was performed on Visit 6 (study Day 10 to 12). Thirteen (13) samples for the determination of tacrolimus concentrations in whole blood in the 0-24 h interval were taken at the following times: 0.00 (within 5 minutes before the morning dose), 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 16.00, 20.00 and 24.00 h post-dose. Minimum (Cmin) and maximum (Cmax) observed blood concentration following a single dose, obtained directly from the blood concentration versus time curves. It was obtained directly from the experimental data without interpolation. Overall results have been reported.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Visit 6 (Day 10 to Day 12) - day time
|
||||||||||||
|
|||||||||||||
Notes [9] - PK population |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
8_Everolimus day time tmax | ||||||||
End point description |
A 24-hour multiple blood sampling for PK assessment was performed on Visit 6 (study Day 10 to 12). Thirteen (13) samples for the determination of tacrolimus concentrations in whole blood in the 0-24 h interval were taken at the following times: 0.00 (within 5 minutes before the morning dose), 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 16.00, 20.00 and 24.00 h post-dose.
Time from dosing to Cmax (tmax), reported using actual times. Overall results have been reported.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Visit 6 (Day 10 to Day 12) - day time
|
||||||||
|
|||||||||
Notes [10] - PK population |
|||||||||
No statistical analyses for this end point |
|
|||||||
End point title |
9_Everolimus day time linear correlation coefficient between AUC12 and Cmin | ||||||
End point description |
A 24-hour multiple blood sampling for PK assessment was performed on Visit 6 (study Day 10 to 12). Thirteen (13) samples for the determination of tacrolimus concentrations in whole blood in the 0-24 h interval were taken at the following times: 0.00 (within 5 minutes before the morning dose), 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 16.00, 20.00 and 24.00 h post-dose.
Linear correlation refers to linear correlation coefficent (R2) between Cmin and AUC12.
Overall results have been reported expressed as a pure number to be multiplied by 10(-4).
|
||||||
End point type |
Secondary
|
||||||
End point timeframe |
Visit 6 (Day 10 to Day 12) - day time
|
||||||
|
|||||||
Notes [11] - PK population |
|||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
End point title |
10_Serum creatinine | ||||||||||||||||||||||||||||||
End point description |
For serum creatinine, baseline was defined as Visit 1 (screening) evaluation. Change from baseline for serum creatinine results have been reported from day 1 to month 6.
|
||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||
End point timeframe |
Renal function was evaluated measuring serum creatinine on blood samples taken at each visit (before transplant and on Day 1, 3, 5, 7, 10 and Month 1, 2, 3, 4, 5 and 6).
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Notes [12] - ITT population |
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
11_Estimated glomerular filtration rate (eGFR) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
The eGFR was calculated with different methods for each site, therefore at the DRM it was decided to derive the eGFR. It was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
For eGFR, baseline was defined as Visit 1 (screening) evaluation. Actual valueas and Change from baseline for eGFR results have been reported from day 1 to month 6.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Analised before transplant (screening) and on Day 1, 3, 5, 7, 10 and Month 1, 2, 3, 4, 5 and 6.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [13] - ITT Population |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
12_Treatment failure rate | ||||||||||||||||
End point description |
Efficacy endpoint.
Treatment failure rate, a composite endpoint,including biopsy proven acute rejection (BPAR), graft failure, death and lost to follow up, and the rate of each component of composite endpoint. Overall results have been reported.
Note: BPAR= biopsy proven acute rejection.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Within 6 months.
|
||||||||||||||||
|
|||||||||||||||||
Notes [14] - ITT population |
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
AE, SAE and ADR were collected throughout the study. From Visit 1 (screening) to Visit 12 (month 6).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
19.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Study Treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
all the subjects receiving the study drugs (Envarsus® and everolimus) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 1% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported. |